Technical Analysis for PSTV - Plus Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.19 | 1.71% | 0.02 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 1.71% | |
| Earnings Movers | Other | 1.71% |
| Alert | Time |
|---|---|
| Rose Above Lower Bollinger Band | about 13 hours ago |
| Up 3% | about 13 hours ago |
| Up 2% | about 13 hours ago |
| Up 1% | about 13 hours ago |
| Down 5% | 4 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/14/2024
Plus Therapeutics, Inc. Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Clinical Medicine Pharmaceutical Disease Drugs Ovarian Cancer Small Cell Lung Cancer Blastoma Glioblastoma Multiple Myeloma Sarcoma Stage Pharmaceutical Pegylation Breast And Ovarian Cancer Docetaxel Doxorubicin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.6702 |
| 52 Week Low | 1.145 |
| Average Volume | 87,326 |
| 200-Day Moving Average | 1.72 |
| 50-Day Moving Average | 1.40 |
| 20-Day Moving Average | 1.31 |
| 10-Day Moving Average | 1.28 |
| Average True Range | 0.11 |
| RSI (14) | 39.39 |
| ADX | 10.27 |
| +DI | 17.81 |
| -DI | 22.26 |
| Chandelier Exit (Long, 3 ATRs) | 1.15 |
| Chandelier Exit (Short, 3 ATRs) | 1.50 |
| Upper Bollinger Bands | 1.45 |
| Lower Bollinger Band | 1.18 |
| Percent B (%b) | 0.05 |
| BandWidth | 21.21 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0121 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.25 | ||||
| Resistance 3 (R3) | 1.25 | 1.23 | 1.24 | ||
| Resistance 2 (R2) | 1.23 | 1.21 | 1.23 | 1.24 | |
| Resistance 1 (R1) | 1.21 | 1.21 | 1.20 | 1.21 | 1.23 |
| Pivot Point | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 |
| Support 1 (S1) | 1.17 | 1.17 | 1.16 | 1.17 | 1.15 |
| Support 2 (S2) | 1.15 | 1.17 | 1.15 | 1.14 | |
| Support 3 (S3) | 1.13 | 1.15 | 1.14 | ||
| Support 4 (S4) | 1.13 |
